Telmisartan-Amlodipine: Uses, Dosage & Safety Information

Telmisartan-Amlodipine

Telmisartan-Amlodipine

Telmisartan-Amlodipine

Telmisartan + Amlodipine
Pairing of an angiotensin receptor blocker with a calcium channel blocker, whose original brand from 2009 is discontinued, now sold as generics for raised readings. It may start treatment when two drugs are needed, ankle swelling tracks the calcium-blocker share, and it is unsafe in pregnancy.
  • ActiveIngredient: Telmisartan + Amlodipine
  • DosageForm: Tablet
  • Dosage: 40/5 mg, 40/10 mg, 80/5 mg, 80/10 mg
  • Indications: Hypertension
  • Manufacturer: Multiple ANDA holders
  • Storage: 25°C (77°F); excursions 15–30°C
  • Drug Status: Prescription Only

What is Telmisartan-Amlodipine?

Telmisartan-amlodipine combines telmisartan, an angiotensin II receptor blocker, with amlodipine, a calcium channel blocker, in one tablet for high blood pressure. The original brand, Twynsta, is listed as discontinued, and the combination is now supplied as generic tablets. It can be used as a first treatment in people likely to need several drugs, to add to either component alone, or to replace both taken separately. It carries a boxed warning against use in pregnancy.1

Twynsta brand discontinued; generics available
Twynsta (NDA 022401, approved October 2009) is listed as discontinued; generic telmisartan-amlodipine tablets remain FDA-approved.2

Approved products and generic therapeutic-equivalence ratings are listed in the FDA Orange Book.3

The two drugs lower blood pressure by different routes: telmisartan blocks angiotensin II, while amlodipine relaxes arterial smooth muscle by blocking calcium entry, and their pharmacokinetics are not altered when they are given together.1

Telmisartan side effects are uncommon and independent of dose, whereas amlodipine causes dose-dependent ankle swelling, so lowering the amlodipine share can ease that problem.

The tablets are bilayer: one layer contains amlodipine and the other telmisartan, each with its own colour and code.

Most of the combined effect appears within two weeks, and it was larger than either drug alone at every assessment through eight weeks.1

Response was similar in older and younger patients and in men and women, and approached that in non-Black patients among the limited number of Black participants.1

The combination is one of the blood pressure medicines; amlodipine with olmesartan is a similar pairing.

How to Take Telmisartan-Amlodipine

Once a day, food optional

Take one tablet once a day, with or without food.1

Allow two weeks

Most of the effect appears within two weeks; your prescriber waits at least that long before raising the dose.

If you are expecting a baby

Stop taking it and contact your doctor as soon as you know or suspect you are expecting a baby.

Chest pain

Report new or worsening chest pain after starting or increasing the dose.

Ankle swelling

Ankle swelling comes mostly from the amlodipine component; tell your doctor, who may lower that part of the dose.

Getting up slowly

Dizziness can occur, especially after a dose increase; rise slowly from sitting or lying.

Simvastatin

If you take simvastatin, your prescriber will keep its dose low while on this combination.

Other medicines

Tell your doctor about anti-inflammatory painkillers, lithium, digoxin and potassium supplements, which interact with telmisartan.

Nursing a baby

Tell your doctor if you plan to nurse a baby; the labelling advises against it during treatment.

What Are the Side Effects of Telmisartan-Amlodipine?

In the factorial study, only ankle swelling, dizziness and back pain occurred at least 2% more often than with placebo, and each led to stopping in 0.5% of patients or fewer.

Telmisartan-Amlodipine vs Placebo
FrequencyEffectNotes
Common — 4.8% (placebo 0%)Peripheral oedema (ankle swelling)Factorial study
Common — 3% (placebo 2.2%)DizzinessFactorial study
Common — 2.2% (placebo 0%)Back painFactorial study
Uncommon — 0.5% or lessStopped because of oedema, dizziness or low blood pressureFactorial study
Frequency not established (labelled)Worsening angina or heart attack after starting, worsening heart failureWarnings

Source: 1

Seek immediate medical attention if:
  • New or worsening chest pain
  • Fainting or severe dizziness
  • Swelling of the face, lips, tongue or throat
  • Breathlessness or rapid weight gain
Clinical details

The combination has been evaluated for safety in more than 3,700 patients with hypertension, about 1,900 of them for at least six months.

What is Telmisartan-Amlodipine Used For?

Telmisartan-amlodipine is indicated for high blood pressure, alone or with other antihypertensive agents, and as initial therapy in people likely to need multiple drugs to reach their blood pressure goal.1

Factorial study

In 1,461 patients with a mean starting pressure of 153/102 mmHg, the four main combinations lowered seated trough pressure by about 19–24/10–14 mmHg more than placebo, compared with about 12/7–8 mmHg for telmisartan alone and 13–18/7–11 mmHg for amlodipine alone.1

Switching and starting

Treatment can start at one of the two lower-amlodipine strengths; the dose may be increased after at least two weeks, usually one component at a time. People with dose-limiting side effects on amlodipine can switch to a tablet with less amlodipine.

Heart conditions

Symptomatic low blood pressure is possible, particularly with severe aortic stenosis; heart failure is monitored for worsening; and worsening angina or a heart attack can develop after starting or increasing the dose, particularly in severe obstructive coronary disease.

Liver, kidney and age

People with liver insufficiency or biliary obstruction, and those with severe kidney impairment, are titrated slowly. Of 3,282 patients in combination trials, 18% were 65 or older, with no overall differences in safety or effectiveness.

Interactions Alcohol:

Consult your doctor
Alcohol is not addressed in this labelling; since both can lower blood pressure, check with your doctor.

Interactions Other Medications:

Use with caution
Simvastatin, NSAIDs, lithium and digoxin interact; aliskiren is contraindicated in diabetes.

Special Groups Pregnancy:

Unsafe
Can cause fetal harm; stop as soon as pregnancy is detected.

Special Groups Breastfeeding:

Unsafe
The labelling advises against breastfeeding during treatment.

Special Groups Elderly:

Safe if prescribed
No overall differences in safety or effectiveness were seen in patients aged 65 or older.

Special Groups Children:

Unsafe
Safety and effectiveness in children have not been established.

Effects on Activities Driving:

Use with caution
Dizziness can occur; see how you react before driving.

Effects on Activities Operating Machinery:

Use with caution
Do not operate dangerous machinery while dizzy.

Ankle swelling depends on amlodipine dose

Amlodipine side effects, mainly ankle swelling, are dose-dependent, while telmisartan side effects are not, so the amlodipine part is the one to reduce if swelling limits treatment.1

Brand discontinued

Twynsta is listed as discontinued, so the combination is dispensed as generics, which must be bioequivalent to their reference product.4

Where it comes from

Telmisartan-amlodipine is prescription-only in the US; the FDA’s BeSafeRx guidance lists four signs of a lawful pharmacy website.5

Critical Warnings for Telmisartan-Amlodipine Use

Contraindications

The combination is contraindicated with known hypersensitivity, such as anaphylaxis or angioedema, to telmisartan, amlodipine or any component, and with aliskiren in people with diabetes.1

Fetal toxicity

Second- and third-trimester exposure reduces fetal kidney function and can cause fetal and neonatal injury or death; the tablets are stopped as soon as pregnancy is detected.

Low blood pressure

Volume or salt depletion is corrected before starting, and symptomatic hypotension is particularly possible with severe aortic stenosis.

Heart

Worsening angina or a heart attack can follow starting or increasing amlodipine, especially in severe obstructive coronary disease, and heart failure is monitored.

Liver, kidney and dual blockade

Slow titration is used in liver or severe kidney impairment, and combining with an ACE inhibitor is avoided.

See Interactions for the full list of drug combinations.

Dosage

Telmisartan-Amlodipine Doses
FormulationActive IngredientsClinical Note
Tablets (telmisartan/amlodipine)Telmisartan-amlodipine40/5, 40/10, 80/5, 80/10 mg
Initial therapyTelmisartan-amlodipine40/5 or 80/5 mg once daily
TitrationTelmisartan-amlodipineAfter ≥2 weeks; maximum 80/10 mg
Dose-limiting amlodipine effectsTelmisartan-amlodipineSwitch to a lower amlodipine strength
Liver: insufficiency or biliary obstructionTelmisartan-amlodipineTitrate slowly
Kidney: severe impairmentTelmisartan-amlodipineTitrate slowly

Source: 1

Exceeding the dose
Overdose may cause low blood pressure, dizziness and a fast heart rate from telmisartan and marked vasodilation with hypotension from amlodipine; telmisartan is not removed by haemodialysis.1

Marketed strengths and their labelers are listed in the FDA National Drug Code Directory.6

What Does Telmisartan-Amlodipine Interact With?

Interactions by Severity
Interacting SubstanceEffect and RiskSeverityDocumentation
SimvastatinHigher simvastatin levels; limit to 20 mg/dayMajorGood — labelled
NSAIDsKidney impairment; reduced effectModerateGood — labelled
Aliskiren (diabetes); ACE inhibitorsKidney impairment, hypotension, hyperkalaemiaMajorGood — labelled
LithiumLithium toxicityMajorGood — labelled
DigoxinHigher digoxin levelsModerateGood — labelled

Source: 1

The Twynsta brand is listed as discontinued; generic telmisartan-amlodipine tablets are available.
40/5, 40/10, 80/5 and 80/10 mg of telmisartan and amlodipine.
Yes, if you are likely to need more than one drug.
Ankle swelling comes mainly from amlodipine and depends on its dose.
No. It can harm the fetus and is stopped as soon as pregnancy is detected.

Evidence scope

What we know
  • The main combinations lowered blood pressure by about 19–24/10–14 mmHg more than placebo.
  • It can be a first treatment when several drugs are likely to be needed.
  • Ankle swelling affected 4.8% versus 0% on placebo.
  • The Twynsta brand is discontinued.
What remains uncertain
  • Safety and effectiveness in children.
  • The effect in Black patients with certainty; numbers were limited.
  • Whether the combination itself reduces cardiovascular events.

Source: 1

What has been reported to the FDA

Reports to the FDA naming telmisartan are summarised on the Micardis page, and those naming amlodipine on the amlodipine besylate page.7

Who was this medicine studied in?

One placebo-controlled factorial study randomised 1,461 patients, two active-controlled studies tested the combination further, and safety data cover more than 3,700 patients.1

Who this is and is not appropriate for

Not for anyone hypersensitive to telmisartan or amlodipine, with aliskiren in diabetes, in pregnancy, or combined with an ACE inhibitor.

Adults with high blood pressure needing two drugs, from the start or after one drug has not been enough.

Where to report and verify

Routing to Official Registries
What you needWhere to go
Report a side effectFDA MedWatch
Pregnancy-specific dataMotherToBaby
Full prescribing informationDailyMed
Verify a pharmacy websiteFDA BeSafeRx · LegitScript

References

  1. FDA label, Telmisartan and Amlodipine Tablets USP (Lupin Pharmaceuticals; ANDA 201586)
    Revised 2023-12 · Accessed 2026-10-23
    Used for: indications incl. initial therapy, dosing, contraindications, warnings, adverse reactions, interactions, specific populations, overdose, factorial study.
    dailymed.nlm.nih.gov — telmisartan/amlodipine SPL
  2. Drugs@FDA
    Record accessed 2026-10-23
    Used for: application and marketing status.
    accessdata.fda.gov — Drugs@FDA
  3. FDA Orange Book
    Accessed 2026-10-23
    Used for: reference and generic listings.
    accessdata.fda.gov — Orange Book
  4. FDA — Generic Drugs: Questions & Answers
    Accessed 2026-10-23
    Used for: requirements for generic equivalence (same active ingredient, strength, bioequivalence).
    fda.gov — Generic Drugs Q&A
  5. FDA BeSafeRx — signs of a safe pharmacy website (flyer)
    Accessed 2026-10-23
    Used for: four signs of a lawful pharmacy website.
    fda.gov — BeSafeRx
  6. FDA National Drug Code Directory
    Directory accessed 2026-10-23
    Used for: marketed products and strengths.
    accessdata.fda.gov — NDC Directory
  7. FDA Adverse Event Reporting System (openFDA)
    Data cut 2026-07-30 · Accessed 2026-10-23
    Used for: report totals and the ten most frequent terms.
    open.fda.gov — drug adverse event API

How this page was sourced

Clinical, dosing and safety facts come from current FDA labelling for generic telmisartan-amlodipine tablets.

Brand status comes from Drugs@FDA; report summaries are on the Micardis and amlodipine besylate pages.

Disclaimer: The information on this site is provided for informational purposes only and is not medical advice. It does not replace professional medical consultation, diagnosis, or treatment. Do not self-medicate based on the information presented on this site. Always consult with a doctor or other qualified healthcare professional before making any decisions about your health.

Medicine graph

Boxed warning

  • WARNING: FETAL TOXICITY

Contraindications (FDA label)

  • Do not co-administer aliskiren with telmisartan and amlodipine tablets in patients with diabetes.
  • Known hypersensitivity (e.g., anaphylaxis or angioedema) to telmisartan, amlodipine or any other component of this product.

FDA label: ANDA202516